{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:14:51Z","timestamp":1789226091685,"version":"build-2803163510"},"reference-count":90,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ViiV Healthcare"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>After a decade of dolutegravir (DTG) use in various antiretroviral therapy combinations and in diverse populations globally, it is critical to identify HIV strains with reduced drug susceptibility and monitor emergent resistance in people living with HIV who experience virologic failure while on DTG-based regimens. We searched the PubMed, Embase, and Cochrane databases to identify studies that reported DTG resistance-associated mutations (RAMs) emerging under selection pressure. Our review showed that RAMs conferring resistance to DTG were rare in 2-drug and 3-drug regimens used in real-world cohorts, corroborating data from clinical trials. The potency of DTG in maintaining virologic suppression was demonstrated, even in cases of pre-existing resistance to companion drugs in the regimen. Estimates of DTG RAMs depended on the population and certain risk factors, including monotherapy, baseline resistance or lack of genotypic testing, treatment history and prior virologic failure, and suboptimal treatment adherence. The RAMs detected after virologic failure, often in heavily treatment-experienced individuals with prior exposure to integrase strand transfer inhibitors, were G118R, E138K, G140A\/C\/R\/S, Q148H\/K\/R, N155H, and R263K. Overall, these data highlight the durable effectiveness and high barrier to resistance of DTG as part of combination antiretroviral therapy in a wide variety of settings.<\/jats:p>","DOI":"10.3390\/v15122426","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T03:16:33Z","timestamp":1702610193000},"page":"2426","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings"],"prefix":"10.3390","volume":"15","author":[{"given":"Cassidy","family":"Henegar","sequence":"first","affiliation":[{"name":"ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Letang","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, P.T.M., Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolan","family":"Wang","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Hicks","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dainielle","family":"Fox","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9296-367X","authenticated-orcid":false,"given":"Bryn","family":"Jones","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 980 Great West Road, Brentford TW8 9GS, Middlesex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"de Ruiter","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 980 Great West Road, Brentford TW8 9GS, Middlesex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vani","family":"Vannappagari","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"ref_1","unstructured":"European AIDS Clinical Society (2023, October 31). Guidelines Version 12.0. Available online: https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2325958219867325","DOI":"10.1177\/2325958219867325","article-title":"Optimizing antiretroviral therapy in treatment-experienced patients living with HIV: A critical review of switch and simplification strategies. An opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy","volume":"18","author":"Chastain","year":"2019","journal-title":"J. Int. Assoc. Provid. AIDS Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Nickel, K., Halfpenny, N.J.A., Snedecor, S.J., and Punekar, Y.S. (2021). Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-na\u00efve patients infected with HIV-1: An update on a systematic review and network meta-analysis. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-05850-0"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s40121-021-00522-7","article-title":"HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: A systematic literature review","volume":"10","author":"Patel","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_6","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2023, October 05). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/QAD.0000000000001845","article-title":"The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: What are the issues?","volume":"32","author":"Vitoria","year":"2018","journal-title":"AIDS"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/cid\/ciac972","article-title":"Transmitted drug resistance to integrase-based first-line human immunodeficiency virus antiretroviral regimens in Mediterranean Europe","volume":"76","author":"Fuentes","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s15010-021-01668-9","article-title":"Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018\u20132020)","volume":"49","author":"Yang","year":"2021","journal-title":"Infection"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/cid\/ciab583","article-title":"Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014\u20132018","volume":"74","author":"McClung","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkz417","article-title":"WHO HIVResNet Working Groups. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance","volume":"75","author":"Tzou","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","first-page":"559","article-title":"2022 update of the drug resistance mutations in HIV-1","volume":"30","author":"Wensing","year":"2022","journal-title":"Top. Antivir. Med."},{"key":"ref_13","unstructured":"World Health Organization (2023, October 31). HIV Drug Resistance Report. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240038608."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: Dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: Week 96 and week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"ref_17","first-page":"549","article-title":"International Study of Patients with HIV on Rifampicin ING study group. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: A multicenter, noncomparative, open-label, randomized trial","volume":"70","author":"Dooley","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/S2352-3018(17)30095-4","article-title":"Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): Week 48 results from a randomised, open-label, non-inferiority, phase 3b study","volume":"4","author":"Orrell","year":"2017","journal-title":"Lancet HIV"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naive adults with HIV-1 infection","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"ofad101","DOI":"10.1093\/ofid\/ofad101","article-title":"Sustained virologic suppression with dolutegravir\/lamivudine in a test-and-treat setting through 48 weeks","volume":"10","author":"Rolle","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3851\/IMP3166","article-title":"Dolutegravir\/abacavir\/lamivudine versus current ART in virally suppressed patients (STRIIVING): A 48-week, randomized, non-inferiority, open-label, phase IIIb study","volume":"22","author":"Trottier","year":"2017","journal-title":"Antivir. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAI.0000000000002449","article-title":"Brief report: Durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials","volume":"85","author":"Orkin","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Results through week 144 from the phase 3, noninferiority TANGO randomized trial","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): Week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","unstructured":"Wang, R., Horton, J., Joshi, A., Gebremedhin, N., Wynne, B., Griffith, S., and Underwood, M. (August, January 29). Low level of virologic failure and resistance in ART-experienced, integrase inhibitor-naive participants receiving dolutegravir (DTG) and nucleoside reverse transcriptase inhibitors (NRTIs) combined regimens: 10-year follow-up in the SAILING study. Proceedings of the 24th International AIDS Conference, Montreal, QU, Canada. Poster EPB158."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13596535221077487","DOI":"10.1177\/13596535221077487","article-title":"Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study","volume":"27","author":"Brown","year":"2022","journal-title":"Antivir. Ther."},{"key":"ref_28","unstructured":"Ackerman, P., Wilkin, T., Pierce, A., Chabria, S., Wang, M., Clark, A., and Lataillade, M. (2021, January 18\u201321). Clinical impact of antiretroviral agents used in optimized background therapy with fostemsavir in heavily treatment-experienced adults with HIV-1: Exploratory analyses of the phase 3 BRIGHTE study. Proceedings of the 11th IAS Conference on HIV Science, Virtual. Poster PEB155."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103284","DOI":"10.1016\/j.drugpo.2021.103284","article-title":"Towards equity for people who inject drugs in HIV prevention drug trials","volume":"96","author":"Brody","year":"2021","journal-title":"Int. J. Drug Policy"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/aid.2014.0205","article-title":"Sex, age, race and intervention type in clinical studies of HIV cure: A systematic review","volume":"31","author":"Johnston","year":"2015","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Diaz, R.S., Hunter, J.R., Camargo, M., Dias, D., Galinskas, J., Nassar, I., de Lima, I.B., Caldeira, D.B., Sucupira, M.C., and Schechter, M. (2023). Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08288-8"},{"key":"ref_32","unstructured":"Perry, S., Abadie, M., Mpango, L., Nyapokoto, C.M., and Mthethwa, N. (2023, January 23\u201326). HIV drug resistance trends among 251 treatment experienced children and young adults (0\u201324 years). Proceedings of the 12th IAS Conference on HIV Science, Brisbane, Australia. Poster EPB0260."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Marcelin, A.-G., Souli\u00e9, C., Wirden, M., Charpentier, C., Descamps, D., and Calvez, V. (2023, January 18\u201321). 3-Year analysis of emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second generation INSTIs in 2- and 3-drug regimens (Virostar study). Proceedings of the 19th European AIDS Conference, Warsaw, Poland. Poster eP.B1.025.","DOI":"10.1093\/jac\/dkae377"},{"key":"ref_34","unstructured":"Marom, R., Zaltz, N., Ziv-Baran, T., Levinson, T., Tau, L., Girshengorn, S., Ahsanov, S., Matus, N., Adler, A., and Turner, D. (2023, January 18\u201321). Drug resistance mutations conferring resistance to integrase inhibitors among people living with HIV in Tel Aviv, between the years 2010\u20132020: Prevalence and risk factors. Proceedings of the 19th European AIDS Conference, Warsaw, Poland. Poster eP.B1.010."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/jac\/dkad101","article-title":"Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings","volume":"78","author":"Armenia","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","first-page":"177","article-title":"Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus","volume":"73","author":"Castagna","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jac\/dkab367","article-title":"Dolutegravir-based dual maintenance regimens combined with lamivudine\/emtricitabine or rilpivirine: Risk of virological failure in a real-life setting","volume":"77","author":"Deschanvres","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.idnow.2021.12.005","article-title":"COPEDOL: A two-year observational study in pretreated HIV-1-infected patients switching to a dolutegravir-based regimen","volume":"52","author":"Landman","year":"2022","journal-title":"Infect. Dis. Now."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/hiv.13500","article-title":"Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study","volume":"24","author":"Palmier","year":"2023","journal-title":"HIV Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jac\/dkz478","article-title":"Long-term follow-up of HIV-infected patients on dolutegravir monotherapy","volume":"75","author":"Tebano","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S2352-3018(22)00136-9","article-title":"Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: A prospective cohort study","volume":"9","author":"Schramm","year":"2022","journal-title":"Lancet HIV"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/QAD.0000000000003480","article-title":"Real world use of dolutegravir two drug regimens","volume":"37","author":"Bowman","year":"2023","journal-title":"AIDS"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","volume":"31","author":"Lepik","year":"2017","journal-title":"AIDS"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Seatla, K.K., Maruapula, D., Choga, W.T., Ntsipe, T., Mathiba, N., Mogwele, M., Kapanda, M., Nkomo, B., Ramaabya, D., and Makhema, J. (2021). HIV-1 subtype C drug resistance mutations in heavily treated patients failing integrase strand transfer inhibitor-based regimens in Botswana. Viruses, 13.","DOI":"10.3390\/v13040594"},{"key":"ref_45","unstructured":"Bhatt, N., Ismail, N., Magule, C., Hussein, C., Meque, I., Couto, A., Nhangave, A., Muteerwa, A., Bonou, M., and Ramos, A. (2023, January 23\u201326). HIV drug resistance profile in clients experiencing treatment failure after the transition to a dolutegravir-based, first-line antiretroviral treatment regimen in Mozambique. Proceedings of the 12th IAS Conference on HIV Science, Brisbane, Australia. Poster LBEPB16."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1093\/jac\/dkad195","article-title":"Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: A cross-sectional analysis of a Northeast Nigerian cohort","volume":"78","author":"Abdullahi","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Gil, H., Delgado, E., Benito, S., Moreno-Lorenzo, M., Thomson, M.M., and Spanish Group for the Study of Antiretroviral Drug Resistance (2022). Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.1051096"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e733","DOI":"10.1016\/S2352-3018(23)00228-X","article-title":"HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: A collaborative cohort analysis","volume":"20","author":"Loosli","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3851\/IMP3082","article-title":"Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results","volume":"22","author":"Oldenbuettel","year":"2017","journal-title":"Antivir. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/jac\/dkw078","article-title":"Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression","volume":"71","author":"Rojas","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jgar.2019.07.015","article-title":"Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors","volume":"20","author":"Scutari","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"ofz377","DOI":"10.1093\/ofid\/ofz377","article-title":"Resistance in patients failing integrase strand transfer inhibitors: A call to replace raltegravir with dolutegravir in third-line treatment in South Africa","volume":"6","author":"Steegen","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/jac\/dkx090","article-title":"Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response","volume":"72","author":"Requena","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/cid\/ciad116","article-title":"Clinical perspective on human immunodeficiency virus care of Ukrainian war refugees in Poland","volume":"76","author":"Parczewski","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_55","unstructured":"Chieffo, G., Ghosn, J., Krivine, A., and Salmon, D. (2017, January 25\u201327). Clinical outcome of heavily treatment-experienced HIV-1 patients harbouring a virus resistant to integrase inhibitors: A French cohort study. Proceedings of the 16th European AIDS Conference, Milan, Italy. Poster PE6\/12."},{"key":"ref_56","unstructured":"L\u00f3pez Brull, \u00c1., T\u00e9llez, R., Cerd\u00e1 Montagud, A., Calabia, O., Llorente, P., Mart\u00edn Garc\u00eda, I., Cabello, A., and G\u00f3rgolas, M. (2019, January 10\u201313). Integrase inhibitor resistance mutations: Cohort of HIV-1 patients at the Jim\u00e9nez D\u00edaz Foundation Hospital. Proceedings of the 11th GeSIDA National Congress, Toledo, Spain."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S545","DOI":"10.1093\/ofid\/ofac492.1102","article-title":"HIV-1 drug resistance in patients failing integrase strand transfer inhibitor-based regimens in Rhode Island, USA","volume":"9","author":"Nagel","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_58","first-page":"24","article-title":"Emerging patterns of integrase inhibitor resistance","volume":"14","author":"Nithianathan","year":"2013","journal-title":"HIV Med."},{"key":"ref_59","unstructured":"Pulido, F., Matarranz, M., Garc\u00eda-Mu\u00f1oz, C., Hernando, A., Bisbal, O., Lagarde, M., Dom\u00ednguez-Dom\u00ednguez, L., and Rubio, R. (December, January 29). Incidence of dolutegravir (DTG) discontinuations in a real-life cohort (HIV-DOC). Proceedings of the 8th GeSIDA National Congress, Donostia-San Sebasti\u00e1n, Spain."},{"key":"ref_60","unstructured":"Viciana, I., Garc\u00eda P\u00e9rez, C., Gonz\u00e1lez-Domenech, C.M., G\u00f3mez-Ayerbe, C., Bard\u00f3n, P., Palacios, R., Casta\u00f1o, M., del Arco, A., T\u00e9llez, F., and Clavijo, E. (2018, January 28\u201331). Prevalence of integrase inhibitor resistance mutation in patients with therapeutic failure. Proceedings of the HIV Drug Therapy Glasgow 2018, Glasgow, UK. Poster P300."},{"key":"ref_61","unstructured":"Wiesmann, F., Maennling, A., Naeth, G., Braun, P., and Knechten, H. (2022, January 23\u201326). Development of second generation integrase inhibitor resistance over the last six years in Germany. Proceedings of the HIV Drug Therapy Glasgow 2022, Glasgow, UK. Poster 221."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jac\/dkad010","article-title":"Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: Findings from a national representative HIV drug resistance survey","volume":"78","author":"Kamori","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1093\/jac\/dkw186","article-title":"Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia","volume":"71","author":"Katlama","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_64","unstructured":"Letang, E., Priest, J., Di Giambenedetto, S., d\u2019Arminio Monforte, A., Casado, J., Cabello-\u00dabeda, A., Hocqueloux, L., Allavena, C., Barber, T.J., and Jha, D. (2022, January 20\u201322). Effectiveness and tolerability of the 2-drug regimen dolutegravir plus lamivudine in people with HIV-1: A systematic literature review of real-world evidence from clinical practice. Proceedings of the BHIVA Spring Conference 2022, Manchester, UK. Poster P023."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/hiv.13050","article-title":"Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: A systematic literature review and meta-analysis of real-world evidence","volume":"22","author":"Punekar","year":"2021","journal-title":"HIV Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","article-title":"Dolutegravir as maintenance monotherapy for HIV (DOMONO): A phase 2, randomised non-inferiority trial","volume":"4","author":"Wijting","year":"2017","journal-title":"Lancet HIV"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11904-007-0010-0","article-title":"Adherence-resistance relationships to combination HIV antiretroviral therapy","volume":"4","author":"Bangsberg","year":"2007","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs. continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority TANGO study","volume":"71","author":"Ajana","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Hidalgo-Tenorio, C., Pasquau, J., Vinuesa, D., Ferra, S., Terr\u00f3n, A., SanJoaqu\u00edn, I., Payeras, A., Mart\u00ednez, O.J., L\u00f3pez-Ruz, M.\u00c1., and Omar, M. (2022). DOLAVI real-life study of dolutegravir plus lamivudine in naive HIV-1 patients (48 weeks). Viruses, 14.","DOI":"10.20944\/preprints202202.0134.v1"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Kuretski, J., Donovan, C., Harper, G., Merrill, D., Mycock, K., Oglesby, A., Metzner, A., and Patarroyo, J. (2022, January 19\u201323). Real-world treatment experience of treatment-na\u00efve people living with HIV who initiated treatment with single-tablet dolutegravir\/lamivudine in a test and treat setting in the United States. Proceedings of the IDWeek 2022, Washington, DC, USA. Poster 1279.","DOI":"10.1093\/ofid\/ofac492.1110"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Cabello-Ubeda, A., L\u00f3pez Bernardo de Quir\u00f3s, J.C., Mart\u00edn Carbonero, L., Sanz, J., Vergas, J., Mena, \u00c1., Torralba, M., Hern\u00e1ndez Segurado, M., Pinto, A., and Tejerina, F. (2022). 48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-na\u00efve adults living with HIV: A multicenter real-life cohort. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0277606"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"ofad526","DOI":"10.1093\/ofid\/ofad526","article-title":"Virologic response to dolutegravir + lamivudine in people with suppressed HIV-1 and historical M184V\/I: A systematic literature review and meta-analysis","volume":"10","author":"Kabra","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_73","unstructured":"Cordova, E., Hernandez Rendon, H., Mingrone, V., Martin, P., Arevalo Calderon, G., Ballivian, J., Seleme, S., and Porteiro, N. (2023, January 23\u201326). Efficacy of dolutegravir plus lamivudine in treatment-na\u00efve people living with HIV without baseline drug-resistance testing: Week 24 results of the randomized D2ARLING study. Proceedings of the 12th IAS Conference on HIV Science, Brisbane, Australia. Poster TUPEB02."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"ofab103","DOI":"10.1093\/ofid\/ofab103","article-title":"Nucleoside reverse-transcriptase inhibitor resistance mutations predict virological failure in human immunodeficiency virus-positive patients during lamivudine plus dolutegravir maintenance therapy in clinical practice","volume":"8","author":"Borghetti","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2021-9-1","DOI":"10.7573\/dic.2021-9-1","article-title":"HIV: How to manage heavily treatment-experienced patients","volume":"11","author":"Spivack","year":"2022","journal-title":"Drugs Context"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"13596535231174774","DOI":"10.1177\/13596535231174774","article-title":"The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review","volume":"28","author":"Aberg","year":"2023","journal-title":"Antivir. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Lam, W.Y., and Fresco, P. (2015). Medication adherence measures: An overview. BioMed Res. Int., 2015.","DOI":"10.1155\/2015\/217047"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1097\/QAI.0000000000003280","article-title":"Impact of treatment adherence on efficacy of dolutegravir + lamivudine and dolutegravir + tenofovir disoproxil fumarate\/emtricitabine: Pooled week 144 analysis of the GEMINI-1 and GEMINI-2 clinical studies","volume":"94","author":"Fernvik","year":"2023","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"23259582221101815","DOI":"10.1177\/23259582221101815","article-title":"Adherence to and forgiveness of 3TC\/DTG in a real-world cohort","volume":"21","author":"Maggiolo","year":"2022","journal-title":"J. Int. Assoc. Provid. AIDS Care"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/QAI.0000000000002142","article-title":"Antiretroviral adherence level necessary for HIV viral suppression using real-world data","volume":"82","author":"Byrd","year":"2019","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12981-021-00358-8","article-title":"Defining the optimal cut-point of self-reported ART adherence to achieve viral suppression in the era of contemporary HIV therapy: A cross-sectional study","volume":"18","author":"Lu","year":"2021","journal-title":"AIDS Res. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2147\/PPA.S192735","article-title":"Adherence to HIV treatment regimens: Systematic literature review and meta-analysis","volume":"13","author":"Altice","year":"2019","journal-title":"Patient Prefer. Adherence"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/505356","article-title":"Rationale and uses of a public HIV drug-resistance database","volume":"194","author":"Shafer","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/jac\/dku199","article-title":"Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity","volume":"69","author":"Osman","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"13596535231201162","DOI":"10.1177\/13596535231201162","article-title":"HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective","volume":"28","author":"Carr","year":"2023","journal-title":"Antivir. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e0067622","DOI":"10.1128\/jvi.00676-22","article-title":"Mutations in the 3\u2019-PPT lead to HIV-1 replication without integration","volume":"96","author":"Richetta","year":"2022","journal-title":"J. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1093\/jac\/dkz377","article-title":"Variability of the HIV-1 3\u2019 polypurine tract (3\u2019PPT) region and implication in integrase inhibitor resistance","volume":"74","author":"Malet","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e00922-17","DOI":"10.1128\/mBio.00922-17","article-title":"Mutations located outside the integrase gene can confer resistance to HIV-1 integrase strand transfer inhibitors","volume":"8","author":"Malet","year":"2017","journal-title":"mBio"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/12\/2426\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:38:41Z","timestamp":1760132321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/12\/2426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":90,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["v15122426"],"URL":"https:\/\/doi.org\/10.3390\/v15122426","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]}}}